- Aileron Therapeutics ALRN announced that a Verification of the initial data from its phase 1b chemoprotection study of ALRN-6924 in p53 mutant breast cancer showed severe neutropenia (Grade 4) and alopecia (hair loss).
- The primary endpoint of the open label phase 1b study was the evaluation of ALRN-6924 in breast cancer patients receiving neoadjuvant or adjuvant treatment with docetaxel, doxorubicin and cyclophosphamide or “TAC” chemotherapy, was the duration and incidence of severe neutropenia in the cycle 1
- Related: Aileron stocks fall after early data from chemoprotectants in lung cancer.
- The incidence of chemotherapy-induced alopecia (hair loss) was a secondary endpoint.
- Based on these results, Aileron has decided to terminate the Phase 1b breast cancer study and further development of ALRN-6924.
- Aileron also announced that it is evaluating various strategic alternatives and has engaged Ladenburg Thalmann & Co Inc. as strategic advisors for this process.
- Aileron will reduce its remaining workforce from 9 to 3 full-time employees over the coming weeks. The company plans to retain the remaining staff to help conduct the strategic alternative review process.
- Price promotion: ALRN shares are down 43.70% to $1.32 on Tuesday’s latest check.
© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
[ad_2]
Source story
